Last update July 6, 2018
A product which has antimuscarinic/anticholinergic effects, similar in action to atropine.
It has antispasmodic properties on smooth muscle. Indicated in functional conditions of the intestine, gall bladder, uterus and bladder.
Since the last update, we have not found published data on its excretion in breastmilk.
Its high binding to plasma proteins makes its excretion in milk unlikely, as indicated by the manufacturer (Unipharm 2018).
There is hardly any published scientific data on this product: fewer than 10 articles (only 4 on humans) collected in PubMed and the last one dates from 2001.
Until there is more published information about this drug in relation to breastfeeding, better known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Atropine in isolated doses is considered compatible with breastfeeding.
During breastfeeding it may be prudent to avoid it or take a minimum dose over short periods of time, monitoring the production of milk as anticholinergics can reduce milk production (De Martino 1980, Bizarro 1980) especially in the first weeks postpartum. It is also advisable to monitor anticholinergic symptoms in the infant: dry mouth, constipation...
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.